KLRS Kalaris Therapeutics Inc.

Price (delayed)

$4.73

Market cap

$112.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.15

Enterprise value

$79.02M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 11

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The ...

Highlights
KLRS's EPS has soared by 96% YoY and by 25% QoQ
The net income is up by 42% year-on-year
The equity has declined by 13% since the previous quarter but it rose by 7% year-on-year
The quick ratio has declined by 15% year-on-year

Key stats

What are the main financial stats of KLRS

KLRS stock price

How has the Kalaris Therapeutics stock price performed over time
Intraday
0.21%
1 week
-8.69%
1 month
-14.47%
1 year
53.07%
YTD
-43.96%
QTD
-18.02%

Financial performance

How have Kalaris Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.63M
Net income
-$44.1M
Gross margin
N/A
Net margin
N/A
The net income is up by 42% year-on-year
The operating income has grown by 20% YoY but it has contracted by 3.2% from the previous quarter

Price vs fundamentals

How does KLRS's price correlate with its fundamentals

Growth

What is Kalaris Therapeutics's growth rate over time

Valuation

What is Kalaris Therapeutics stock price valuation
P/E
N/A
P/B
1.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KLRS's EPS has soared by 96% YoY and by 25% QoQ
The price to book (P/B) is 21% less than the 5-year quarterly average of 2.0 and 17% less than the last 4 quarters average of 1.9
The equity has declined by 13% since the previous quarter but it rose by 7% year-on-year

Efficiency

How efficient is Kalaris Therapeutics business performance
Kalaris Therapeutics's return on invested capital has surged by 83% YoY and by 63% QoQ
KLRS's return on equity has surged by 50% year-on-year
The return on assets rose by 48% year-on-year

Dividends

What is KLRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KLRS.

Financial health

How did Kalaris Therapeutics financials performed over time
The total assets is 166% greater than the total liabilities
The current ratio has contracted by 15% YoY
The quick ratio has declined by 15% year-on-year
Kalaris Therapeutics's debt is 98% less than its equity
The equity has declined by 13% since the previous quarter but it rose by 7% year-on-year
Kalaris Therapeutics's debt has decreased by 2.6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.